The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease

Li, Qiang; Lu, Chuan; Li, Weixia; Huang, Yuxian; Chen, Liang

doi:10.18632/oncotarget.16162

Cited by 28 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found only Lemoine et al's study (11) to be similar to our study. It was conducted mainly in patients who were negative for HBeAg, while other studies enrolled all positive (21) or both patients (20,27,29,30). Another point is that most previous studies were conducted in China but our study and the study by Lemoine et al (11) were conducted in Africa.…”

Section: Discussionmentioning

confidence: 88%

King’s Fibrosis, Fibrosis Index, GPR, and ALBI Score Are Useful Models for Liver Fibrosis in Chronic Hepatitis B Patients Pre- and Post-Treatment

et al. 2019

View full text Add to dashboard Cite

Background: Liver fibrosis is one of the chronic hepatitis B (CHB) indications for treatment. Objectives: We aimed to assess the fibrosis index, FIB-4, King's fibrosis score, albumin-bilirubin (ALBI) score, gamma-glutamyl transferase-platelets (GPR), and gamma-glutamyl transferase-albumin (GAR) ratios as diagnostic models of liver fibrosis in CHB patients. Methods: The study enrolled 217 patients. Liver fibrosis was assessed by transient elastography, which showed 20.3% of the patients had F4 fibrosis. Treatment was given for 33.20 ± 20.94 months. Results: F4 fibrosis patients had higher values (P = 0.001) of Fibrosis index score, FIB-4 score, King's fibrosis score, ALBI score, GPR, and GAR than non-F4 fibrosis patients. All patients had improved values after treatment. The mean treatment-induced changes were comparable in patients with and without virological response. The Fibrosis index of >-32.66 showed 63.64% sensitivity and 91.33% specificity. The FIB-4 score of > 1.88 had 72.73% sensitivity and 91.33% specificity. The King's fibrosis score of > 7.93 demonstrated 90.91% sensitivity and 73.99% specificity. The ALBI score of >-2.7 had 70.45% sensitivity and 86.13% specificity. The GPR value of > 0.69 revealed 70.5% sensitivity and 94.2% specificity. The GAR value of > 1.28 showed 72.73% sensitivity and 46.4% specificity. The GAR was inferior to FIB-4 and GPR (P < 0.05). Conclusions: GPR, fibrosis index, King's fibrosis score, ALBI, and FIB-4 are useful diagnostic models of liver fibrosis in CHB patients.

show abstract

Section: Discussionmentioning

confidence: 88%

King’s Fibrosis, Fibrosis Index, GPR, and ALBI Score Are Useful Models for Liver Fibrosis in Chronic Hepatitis B Patients Pre- and Post-Treatment

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In this study, we observed an interesting fact that serum GGT to platelet ratio was significantly different in AA compared to non‐AA. Recently, few studies have shown that GGT to platelet ratio had a higher predictive values compared to APRI especially in patients with chronic hepatitis B and non‐alcoholic fatty liver disease (NAFLD) . In children, serum GGT has been shown to be an important parameter estimating the severity of liver fibrosis and ultimately portal hypertension .…”

Section: Discussionmentioning

confidence: 99%

“…Recently, few studies have shown that GGT to platelet ratio had a higher predictive values compared to APRI especially in patients with chronic hepatitis B and non-alcoholic fatty liver disease (NAFLD). 23,24 In children, serum GGT has been shown to be an important parameter estimating the severity of liver fibrosis and ultimately portal hypertension. 25 In our study, GGT:platelet ratio was observed to be a significant Children's Healthcare of Atlanta is a tertiary referral centre; therefore, our paediatric AIH cohort may be sicker than has been reported in prior studies.…”

Section: Discussionmentioning

confidence: 99%

Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis

Palle

Naik

Kolachala

et al. 2019

Liver International

View full text Add to dashboard Cite

Background & Aims Most studies on autoimmune hepatitis (AIH) in children are in predominantly Caucasian cohorts. Paediatric AIH in African Americans (AA) is understudied, with a dearth of clinical predictors of outcome, often leading to serious complications and even mortality. The aim of the study was to define disease presentation, progression, response to therapy and outcomes in paediatric AIH in a well‐defined, large, single centre, demographically diverse population. Methods We conducted a review of patients with AIH who were followed at this tertiary liver transplant centre. Clinical and laboratory covariates were assessed with regard to disease presentation, progression and outcomes in AA vs Non‐AA children. Results African Americans patients constituted 42% of this cohort. At 1‐year follow‐up, AA children were receiving significantly higher doses of steroids compared to non‐AA. More AA presented with end‐stage liver disease (ESLD) with high immunoglobulin G and GGT:platelet ratio. After adjusting for other risk factor variables like gender, age at presentation and ESLD, AA children were at 4.5 times higher risk for significant outcome liver transplant/death within the first 12 months of presentation. Post‐transplant, recurrent AIH was seen in 50% of AA vs 8% in non‐AA. Conclusions African American patients with AIH are more likely to present with ESLD and have an increased early risk for transplantation with high likelihood of disease recurrence post‐transplantation. Studies are needed to delineate factors such as inherent biology, genetics and access to care. Early referral and tailored immunosuppressive regimens are required for AA patients with AIH.

show abstract

“…Було вста-новлено найбільшу точність APRI при важкому фіброзі (AUROC 0,77) та цирозі печінки (AUROC 0,86) [35].…”

Section: обговоренняunclassified

Неінвазивна Діагностика Фіброзу Печінки У Хворих Із неалкогольною Жировою Хворобою Печінки

Stepanov

Nedzvetskaya

Yagmur

et al. 2021

GASTRO

View full text Add to dashboard Cite

Резюме. Актуальність. Неалкогольна жирова хвороба печінки (НАЖХП)- ВступНеалкогольна жирова хвороба печінки (НАЖХП) охоплює спектр захворювань, тісно пов'язаних із ме-таболічними факторами ризику. Іншими словами, вона є печінковим проявом метаболічного синдрому. НАЖХП включає стеатоз, неалкогольний стеатогепа-тит (НАСГ) з цирозом або без нього та гепатоцелюляр-ну карциному за відсутності зловживання алкоголем, що визначається як добове споживання алкоголю в пе-рерахунку на чистий спирт більше ніж 30 г для чоло-віків та більше ніж 20 г для жінок [1]. Стеатоз печінки має сприятливий клінічний перебіг, оскільки запаль-не пошкодження печінки не розвивається. Необхідно розрізняти цю форму НАЖХП, що пов'язана зі спри-ятливим довгостроковим прогнозом, і НАСГ, для якого характерно прогресування: приблизно у 20 % пацієнтів із НАСГ розвиваються криптогенний цироз і гепатоце-люлярна карцинома [2].Актуальність проблеми полягає в тому, що НАЖХП є найбільш поширеним захворюванням печінки в за-хідних країнах; патологія охоплює 17-46 % дорос-лого населення з відмінностями залежно від методу діагностики, віку, статі та етнічної приналежності [1]. За даними УЗД, поширеність НАЖХП серед доросло-го населення в цілому становить приблизно 25-30 % у Європі і Сполучених Штатах Америки. Найвища

show abstract

The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease

Cited by 28 publications

References 21 publications

King’s Fibrosis, Fibrosis Index, GPR, and ALBI Score Are Useful Models for Liver Fibrosis in Chronic Hepatitis B Patients Pre- and Post-Treatment

King’s Fibrosis, Fibrosis Index, GPR, and ALBI Score Are Useful Models for Liver Fibrosis in Chronic Hepatitis B Patients Pre- and Post-Treatment

Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis

Неінвазивна Діагностика Фіброзу Печінки У Хворих Із неалкогольною Жировою Хворобою Печінки

Contact Info

Product

Resources

About